The Genitourinary Oncology Program Area is composed of 18 members, spanning 9 Departments within UCLA. In the past competing cycle, investigators from this Program authored 328 publications, of which 167 (51%) were inter-programmatic and 190 (58%) intra-programmatic. 96 (29%) were placed in high-impact ournals. 11 members of this Program Area used 8 out of the 8 JCCC Shared Resources. Peer-reviewed Funding for this program totals $8.7M of which $4.3M is awarded from NCI. As with other Program Areas, JCCC fosters a number of interactive activities and many of the Shared Resources that support investigators in the GU Program Area. During the current grant cycle, funds from the JCCC in the form of CCSG Developmental Funds, institutional support and philanthropic gifts to the GU Program Area total $1,001,382. These funds supported Seed Grants, recruitment/retention, Program Area Leadership support, funding for the use of emerging Shared Resources and trainees. Twelve of the Program Area Members were the recipients of JCCC support. ($500K of these funds were in support of the UCLA Prostate SPORE. These funds were then used to support SPORE-related activities which benefited a larger group of faculty, some of whom are JCCC Members.) The Program seeks to coordinate all clinical activities to deliver optimum care to patients with localized and metastatic tumors. Furthermore, the Program hopes to facilitate the study of new and emerging treatment strategies, especially those translated from basic science research. The goals of the GU Oncology Program are: 1) Creating mouse models of these cancers;2) Perform pre-clinical studies of new therapeutic agents; and 3) Conduct phase l/ll clinical trials of novel anti-cancer drugs.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016042-36
Application #
8208718
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2010-12-01
Budget End
2011-11-30
Support Year
36
Fiscal Year
2011
Total Cost
$63,861
Indirect Cost
Name
University of California Los Angeles
Department
Type
DUNS #
092530369
City
Los Angeles
State
CA
Country
United States
Zip Code
90095
Van Dyk, Kathleen; Bower, Julienne E; Crespi, Catherine M et al. (2018) Cognitive function following breast cancer treatment and associations with concurrent symptoms. NPJ Breast Cancer 4:25
Robinett, Ryan A; Guan, Ning; Lux, Anja et al. (2018) Dissecting Fc?R Regulation through a Multivalent Binding Model. Cell Syst 7:41-48.e5
Chin, Chee Jia; Li, Suwen; Corselli, Mirko et al. (2018) Transcriptionally and Functionally Distinct Mesenchymal Subpopulations Are Generated from Human Pluripotent Stem Cells. Stem Cell Reports 10:436-446
Alban, Tyler J; Alvarado, Alvaro G; Sorensen, Mia D et al. (2018) Global immune fingerprinting in glioblastoma patient peripheral blood reveals immune-suppression signatures associated with prognosis. JCI Insight 3:
Yang, Qing; Fung, Wing K; Li, Gang (2018) Sample size determination for jointly testing a cause-specific hazard and the all-cause hazard in the presence of competing risks. Stat Med 37:1389-1401
Seo, Jai Woong; Tavaré, Richard; Mahakian, Lisa M et al. (2018) CD8+ T-Cell Density Imaging with 64Cu-Labeled Cys-Diabody Informs Immunotherapy Protocols. Clin Cancer Res 24:4976-4987
Ribas, Antoni; Wolchok, Jedd D (2018) Cancer immunotherapy using checkpoint blockade. Science 359:1350-1355
Wang, Hong; Chen, Xiaolin; Li, Gang (2018) Survival Forests with R-Squared Splitting Rules. J Comput Biol 25:388-395
Yu, Jingyi; Seldin, Marcus M; Fu, Kai et al. (2018) Topological Arrangement of Cardiac Fibroblasts Regulates Cellular Plasticity. Circ Res 123:73-85
Hong, Aayoung; Moriceau, Gatien; Sun, Lu et al. (2018) Exploiting Drug Addiction Mechanisms to Select against MAPKi-Resistant Melanoma. Cancer Discov 8:74-93

Showing the most recent 10 out of 767 publications